Business Context and Reporting Period
Company: Village Farms International, Inc. (VFF)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: VFF operates in five segments: Cannabis Canada (Pure Sunfarms, Rose LifeScience), Cannabis U.S. (Balanced Health), Cannabis Netherlands (Leli Holland), Produce (Village Farms Fresh), and Clean Energy (VFCE). The company pivoted significantly in 2025 by privatizing its U.S. produce assets via a joint venture with Vanguard Food LP, classifying these operations as discontinued. The company focuses on Controlled Environment Agriculture (CEA) for cannabis and produce.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Total Sales | $215,937 | $195,907 |
| Gross Profit | $87,682 | $45,801 |
| Gross Margin | 40.6% | 23.4% |
| Net Income (Continuing Ops) | $20,988 | ($27,942) |
| Net Income (Total) | $32,441 | ($35,851) |
| Adjusted EBITDA (Continuing Ops) | $49,852 | $7,374 |
| Cash & Equivalents | $86,252 | $24,631 |
| Working Capital | $95,851 | $53,800 |
| Total Debt (Long-term + Current) | $33,654 | $40,562 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability, reporting a net income of $32.4 million in 2025 compared to a net loss of $35.9 million in 2024. This was driven by a 91% increase in gross profit and the elimination of goodwill impairments recorded in the prior year.
- Discontinued Operations: A significant gain of $19.985 million was recognized from the sale of U.S. produce assets to Vanguard Food LP in May 2025. These operations are now presented as discontinued.
- Segment Performance:
- Cannabis Canada: Sales increased 10% to $163.7 million. International export sales surged 517% year-over-year. Gross margin improved to 44% from 21% in 2024, aided by the absence of the $10.4 million inventory impairment recorded in 2024.
- Cannabis Netherlands: Commenced commercial sales in Q1 2025, generating $9.9 million in revenue and $3.3 million in Adjusted EBITDA.
- Cannabis U.S.: Sales declined 17% to $14.4 million due to regulatory restrictions in eight states and competition from unregulated hemp products. However, the segment avoided the $11.9 million goodwill impairment seen in 2024.
- Produce: Sales decreased 9% to $26.3 million due to a new sales commission structure with Vanguard. Gross margin dropped to 3% from 12%.
- Debt Reduction: Total debt decreased by approximately $6.9 million due to repayments and refinancing activities, including the replacement of older credit facilities with the Pure Sunfarms Secured Credit Facilities.
Guidance, Outlook, and Risks
- Regulatory Risks (U.S.): The November 2025 Appropriations Act redefines "hemp" to include "total THC" (including THCA) and imposes a 0.4mg THC cap per container, effective November 12, 2026. This legislation threatens to recriminalize a substantial majority of the company's U.S. CBD product lines (Balanced Health) unless further legislative action is taken.
- Expansion Plans:
- Canada: Conversion of the remaining half of the Delta 2 greenhouse to cannabis production is underway, expected to increase capacity by 33% by 2027.
- Netherlands: Phase II facility in Groningen is nearing completion, expected to quintuple annualized production to ~10,000 kg upon operation in Q2 2026.
- U.S. Texas: Application for a Texas medicinal cannabis license remains under review; nine conditional licenses were awarded in Dec 2025, but VFF was not a recipient. Three more are expected by April 2026.
- Liquidity: Management believes existing cash ($86.3 million) and credit facilities are sufficient for the next 12 months. A $10 million share repurchase program was authorized in September 2025; $3 million was utilized in Q4 2025.
- Operational Risks: Exposure to energy costs, labor availability (reliance on foreign worker programs in Canada), and potential tariffs on Canadian exports to the U.S.
Key Facts for Investor Verification
- U.S. CBD Regulatory Cliff: Verify the status of the November 2025 Appropriations Act and any pending legislative relief regarding the "total THC" definition and 0.4mg cap effective November 2026, which directly impacts the Balanced Health segment.
- Discontinued Operations Gain: Confirm the final purchase price adjustment for the Vanguard Food LP transaction, as the $19.985 million gain is subject to post-closing adjustments.
- Debt Covenants: Review compliance with financial covenants under the new Pure Sunfarms Secured Credit Facilities and the FCC Term Loan, noting that waivers were required in 2024.
- Inventory Valuation: Assess the current inventory levels and net realizable value, given the $10.4 million write-down in 2024 and the company's exposure to product shelf-life and market price compression.
- International Export Growth: Validate the sustainability of the 517% growth in international medical cannabis exports and the reliance on specific markets (Germany, UK, Australia, New Zealand).